Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Dementia
- Sponsor
- Peking Union Medical College Hospital
- Enrollment
- 2000
- Locations
- 1
- Primary Endpoint
- Incorporating age stratified biomarkers into the diagnosis of dementia
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Biomarkers are important for early and precise diagnosis of dementia. However, the causes of dementia in different age are different. We designed an age stratified dementia cohort and tried to explore biomarkers of different groups of dementia, incorporating neuropsychology, multi-model neuroimaging, metabolics and proteomics based fluid biomarkers as well as genetic biomarkers. Autopsy after clinical follow up help to verify the biomarkers.
Detailed Description
Baseline data collection and cohort establishing: Detailed clinical information including demographic data, clinical history, past history and physical examination are collected. Formatted neuropsychological battery is used in all patients, including screening tests (MMSE, MoCA-PUMCH, ADL, HAD) and domain specific evaluation (Memory, executive function, visual spatial, calculation, language). Samples including serum, CSF, urine, skin, saliva are stored. Every patient is followed up every 6 months. Autopsy brain tissue will be collected if patients died. Multi-model neuroimaging evaluation: Structure and functional brain 3T-MRI; 7T-MRI； PET-CT including FDG, Aβ（18F-AV45）,tau（18F-THK5317, 18F-T807）; EEG Multi-omics biomarkers research: CSF AD biomarkers (Aβ40,42, ptau181, ttau, NfL, Neurogranin), comparison of different methods, including ELISA, Electrochemical, Mass Spectroscopy. The standardization of CSF biomarkers analysis in China. Exploring new fluid biomarkers: CSF and Urine proteomics; CSF and serum glycomics and metabolomics. To explore new biomarkers in differentiation of different causes of dementia, age onset and prognosis of dementia. Genetic biomarkers evaluation: including pathogenic gene mutation panel examination and WES. Data analysis and biomarkers evaluation: Dementia patients are stratified based on age onset, cause of dementia, cognition severity, effect of therapy, prognosis. Identify multi-omics biomarkers in different groups. Comparing the relationships between biomarkers and clinical presentations as well as neuroimaging. Autopsy based accurate diagnosis help further defining biomarkers. Acquiring stratified biomarkers with high sensitivity and specificity.
Investigators
gaojing
Professor, Department of Neurology
Peking Union Medical College Hospital
Eligibility Criteria
Inclusion Criteria
- •Neurodegenerative dementia diagnosis based on 2011 NIA-AA criteria of Dementia
- •Fixed care giver and can follow up regularly
Exclusion Criteria
- •Not demented, including MCI
- •Systemic severe diseases and severe vision or hearing problem effecting follow up and neuropsychological evaluation
- •Without fixed care giver
- •Reject informed consent
- •Expected life shorter than 2 years
Outcomes
Primary Outcomes
Incorporating age stratified biomarkers into the diagnosis of dementia
Time Frame: Through study completion,an average of 5 years
Comparing the relationships between biomarkers and clinical presentations as well as neuroimaging. Incorporate biomarkers into the accurate and early diagnosis of dementia
Secondary Outcomes
- Establishing dementia cohort including detailed clinical information, fluid samples and brain bank(Through study completion,an average of 5 years)
- Exploring 5-10 kinds of age stratified biomarkers, including neuropsychology, neuroimaging, fluid biomarkers and genetic biomarkers(Through study completion,an average of 5 years)